Plasma 25-hydroxyvitamin D and not 1,25-dihydroxyvitamin D is associated with parathyroid adenoma secretion in primary hyperparathyroidism: A cross-sectional study

European Journal of Endocrinology

Volumn 155, Issue 2, 2006, Pages 237-244

  Moosgaard, B ^a   Vestergaard, P ^a   Heickendorff, L ^a   Melsen, F ^a   Christiansen, P ^a   Mosekilde, L ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ALKALINE PHOSPHATASE; CALCITRIOL; CALCIUM; PARATHYROID HORMONE; PHOSPHATE; VITAMIN D RECEPTOR;

ADULT; AGED; ARTICLE; BODY MASS; CALCIUM BLOOD LEVEL; CAUCASIAN; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SECRETION; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENDER; HUMAN; HYPERCALCEMIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; PARATHYROID ADENOMA; PARATHYROID CELL; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROID HORMONE RELEASE; PHOSPHATE BLOOD LEVEL; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY;

ADENOMA; ADULT; AGED; AGED, 80 AND OVER; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPERPARATHYROIDISM, PRIMARY; MALE; MIDDLE AGED; ORGAN SIZE; PARATHYROID GLANDS; PARATHYROID HORMONE; PARATHYROID NEOPLASMS; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 33747738498     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.1.02197     Document Type: Article

References (42)

1. Fraser DR & Kodicek E. Unique biosynthesis by kidney of a biological active vitamin D metabolite. Nature 1970 228 764-766.
2. Brown AJ, Dusso A & Slatopolsky E. Vitamin D. American Journal of Physiology 1999 277 F157-F175.
3. Lalor BC, Mawer EB, Davies M, Lumb GA, Hunt L & Adams PH. Determinants of the serum concentration of 1,25-dihydroxyvitamin D in primary hyperparathyroidism. Clinical Science 1989 76 81-86.
4. Mosekilde L, Charles P & Lindegreen P. Determinants for serum 1,25-dihydroxycholecalciferol in primary hyperparathyroidism. Bone and Mineral 1989 5 279-290.
5. Thakker RV, Fraher LJ, Adami S, Karmali R & O'Riordan JL. Circulating concentrations of 1,25-dihydroxyvitamin D3 in patients with primary hyperparathyroidism. Bone and Mineral 1986 1 137-144.
6. Frølich A, Storm T & Thode J. Does the plasma concentration of 25-hydroxyvitamin D determine the level of 1,25-dihydroxyvitamin D in primary hyperparathyroidism. Mineral and Electrolyte Metabolism 1996 22 203-206.
7. Wortsman J, Haddad JG, Posillico JT & Brown EM. Primary hyperparathyroidism with low serum 1,25-dihydroxyvitamin D levels. Journal of Clinical Endocrinology and Metabolism 1986 62 1305-1308.
8. LoCascio V, Adami S, Galvanini G, Ferrari M, Cominacini L & Tartarotti D. Substrate-product of 1-hydroxylase activity in primary hyperparathyroidism. New England Journal of Medicine 1985 313 1123-1125.
9. Norman AW, Bishop JE, Bula CM, Olivera CJ, Mizwicki MT, Zanello LP, Ishida H & Okamura WH. Molecular tools for study of genomic and rapid signal transduction responses initiated by 1 alpha,25(OH)(2)-vitamin D(3). Steroids 2002 67 457-466.
10. Huhtakangas JA, Olivera CJ, Bishop JE, Zanello LP & Norman AW. The vitamin D receptor is present in caveolae-enriched plasma membranes and binds 1 alpha,25(OH)2-vitamin D3 in vivo and in vitro. Molecular Endocrinology 2004 18 2660-2671.
11. Canalejo A, Almaden Y, Torregrosa V, Gomez-Villamandos JC, Ramos B, Campistol JM, Felsenfeld AJ & Rodriguez M. The in vitro effect of calcitriol on parathyroid cell proliferation and apoptosis. Journal of the American Society of Nephrology 2000 11 1865-1872.
12. Brown AJ, Zhong M, Finch J, Ritter C, McCracken R, Morrissey J & Slatopolsky E. Rat calcium-sensing receptor is regulated by vitamin D but not by calcium. American Journal of Physiology 1996 270 F454-F460.
13. Carling T, Rastad J, Szabo E, Westin G & Akerstrom G. Reduced parathyroid vitamin D receptor messenger ribonucleic acid levels in primary and secondary hyperparathyroidism. Journal of Clinical Endocrinology and metabolism 2000 85 2000-2003.
14. Rao DS, Honasoge M, Divine GW, Phillips ER, Lee MW, Ansari MR, Talpos GB & Parfitt AM. Effect of vitamin D nutrition on parathyroid adenoma weight: pathogenetic and clinical implications. Journal of Clinical Endocrinology and Metabolism 2000 85 1054-1058.
15. Sudhaker RD, Han ZH, Phillips ER, Palnitkar S & Parfitt AM. Reduced vitamin D receptor expression in parathyroid adenomas: implications for pathogenesis. Clinical Endocrinology (Oxf) 2000 53 373-381.
16. Nykjaer A, Dragun D, Walther D, Vorum H, Jacobsen C, Herz J, Melsen F, Christensen EI & Willnow TE. An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3. Cell 1999 96 507-515.
17. Lundgren S, Carling T, Hjalm G, Juhlin C, Rastad J, Pihlgren U, Rask L, Akerstrom G & Hellman P. Tissue distribution of human gp330/megalin, a putative Ca(2+)-sensing protein. Journal of Histochemistry and Cytochemistry 1997 45 383-392.
18. Segersten U, Correa P, Hewison M, Hellman P, Dralle H, Carling T, Akerstrom G & Westin G. 25-hydroxyvitamin D(3)-1alpha-hydroxylase expression in normal and pathological parathyroid glands. Journal of Clinical Endocrinology and Metabolism 2002 87 2967-2972.
19. Correa P, Segersten U, Hellman P, Akerstrom G & Westin G. Increased 25-hydroxyvitamin D3 1alpha-hydroxylase and reduced 25-hydroxyvitamin D3 24-hydroxylase expression in parathyroid tumors-new prospects for treatment of hyperparathyroidism with vitamin D. Journal of Clinical Endocrinology and Metabolism 2002 87 5826-5829.
20. Moosgaard B, Vestergaard P, Heickendorff L, Melsen F, Christiansen P & Mosekilde L. Vitamin D status, seasonal variations, parathyroid adenoma weight and bone mineral density in primary hyperparathyroidism. Clinical Endocrinology (Oxf) 2005 63 506-513.
21. Lumb GA & Stanbury SW. Parathyroid function in human vitamin D deficiency and vitamin D deficiency in primary hyperparathyroidism. American Journal of Medicine 1974 56 833-839.
22. Silverberg SJ, Shane E, Dempster DW & Bilezikian JP. The effects of vitamin D insufficiency in patients with primary hyperparathyroidism. American Journal of Medicine 1999 107 561-567.
23. Souberbielle JC, Cormier C, Kindermans C, Gao P, Cantor T, Forette F & Baulieu EE. Vitamin D status and redefining serum parathyroid hormone reference range in the elderly. Journal of Clinical Endocrinology and Metabolism 2001 86 3086-3090.
24. Souberbielle JC, Lawson-Body E, Hammadi B, Sarfati E, Kahan A & Cormier C. The use in clinical practice of parathyroid hormone normative values established in vitamin D-sufficient subjects. Journal of Clinical Endocrinology and Metabolism 2003 88 3501-3504.
25. Livolsi VA. Parathyroids, morphology and pathology. In The Parathyroids. Basic and Clinical Concepts, pp 1-15. Eds J Bilezikian, R Marcus & MA Levine. California: Academic Press, 2001.
26. Elder G. Pathophysiology and recent advances in the management of renal osteodystrophy. Journal of Bone and Mineral Research 2002 17 2094-2105.
27. Kinoshita Y, Taguchi M, Takeshita A, Miura D, Tomikawa S & Takeuchi Y. 1,25-dihydroxyvitamin d suppresses circulating levels of parathyroid hormone in a patient with primary hyperparathyroidism and coexistent sarcoidosis. Journal of Clinical Endocrinology and Metabolism 2005 90 6727-6731.
28. Holick MF. Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. American Journal of Clinical Nutrition 2004 79 362-371.
29. Parfitt AM. Osteomalacia and related disorders. In Metabolic Bone Diseases and Clinically Related Disorders, pp 327-386. Eds LV Avioli & SM Krane. San Diego: Academic Press, 1998.
30. Glerup H. Investigation on the role of vitamin D in muscle function - A study of muscle function in vitamin D deficient humans and effect of treatment with vitamin D. 1999. Aarhus University, Aarhus, Denmark. Ref Type: Report.
31. Glerup H, Mikkelsen K, Poulsen L, Hass E, Overbeck S, Andersen H, Charles P & Eriksen EF. Hypovitaminosis D myopathy without biochemical signs of osteomalacic involvement. Calcified Tissue International 2000 66 419-424.
32. Lips P, Wiersinga A, van Ginkel FC, Jongen MJ, Netelenbos JC, Hackeng WH, Delmas PD & van der Vijgh WJ. The effect of vitamin D supplementation on vitamin D status and parathyroid function in elderly subjects. Journal of Clinical Endocrinology and Metabolism 1988 67 644-650.
33. Mosekilde L. Vitamin D and the elderly. Clinical Endocrinology (Oxf) 2005 62 265-281.
34. Bolland MJ, Grey AB, Gamble GD & Reid IR. Association between primary hyperparathyroidism and increased body weight: a meta-analysis. Journal of Clinical Endocrinology and Metabolism 2005 90 1525-1530.
35. McCarty MF & Thomas CA. PTH excess may promote weight gain by impeding catecholamine-induced lipolysis-implications for the impact of calcium, vitamin D, and alcohol on body weight. Medical Hypotheses 2003 61 535-542.
36. Bolland MJ, Grey AB & Ames RW. Fat mass is an important predictor of parathyroid hormone levels in postmenopausal women. Bone 2006 38 317-321.
37. Parikh SJ, Edelman M, Uwaifo GI, Freedman RJ, Semega-Janneh M, Reynolds J & Yanovski JA. The relationship between obesity and serum 1,25-dihydroxy vitamin D concentrations in healthy adults. Journal of Clinical Endocrinology and Metabolism 2004 89 1196-1199.
38. Snijder MB, van Dam RM, Visser M, Deeg DJ, Dekker JM, Bouter LM, Seidell JC & Lips P. Adiposity in relation to vitamin D status and parathyroid hormone levels: a population-based study in older men and women. Journal of Clinical Endocrinology and Metabolism 2005 90 4119-4123.
39. Grey A & Reid I. Body weight and bone mineral density in hyperparathyroidism. Annals of Internal Medicine 1995 123 732.
40. Bergenfelz A, Lindblom P, Lindergard B, Valdemarsson S & Westerdahl J. Preoperative normal level of parathyroid hormone signifies an early and mild form of primary hyperparathyroidism. World Journal of Surgery 2003 27 481-485.
41. Grey A, Lucas J, Horne A, Gamble G, Davidson JS & Reid IR. Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiency. Journal of Clinical Endocrinology and Metabolism 2005 90 2122-2126.
42. Kantorovich V, Gacad MA, Seeger LL & Adams JS. Bone mineral density increases with vitamin D repletion in patients with coexistent vitamin D insufficiency and primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism 2000 85 3541-3543.